NEW YORK, March 25, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), ZIOPHARM Oncology, Inc.
(NASDAQ: ZIOP), Aastrom Biosciences, Inc. (NASDAQ: ASTM), Agios
Pharmaceuticals, Inc. (NASDAQ: AGIO), and OncoMed Pharmaceuticals,
Inc. (NASDAQ: OMED). Private wealth members receive these notes
ahead of publication. To reserve complementary membership, limited
openings are available at:
http://www.AnalystsReview.com/register
--
Synta Pharmaceuticals Corp. Analyst Notes
On March 11, 2014, Synta
Pharmaceuticals Corp. (Synta) and QuantumLeap Healthcare
Collaborative jointly announced that Synta's lead drug candidate,
the Hsp90 inhibitor ganetespib, has been selected for study in the
I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your
Therapeutic Response with Imaging And moLecular Analysis 2). "The
selection of ganetespib for the I-SPY 2 program is important
validation of the potential for ganetespib in breast cancer," said
Dr. Iman El-Hariry, Vice President
of Clinical Research at Synta. "This study represents a new
standard for efficient, cutting edge collaborative research, and
has already yielded promising new findings, such as those announced
for investigational agents veliparib and neratinib. We look forward
to participating in the trial." The Companies informed that they
expect enrollment in the ganetespib arm of I-SPY 2 to begin in
2014. The full analyst notes on Synta Pharmaceuticals Corp. are
available to download free of charge at:
http://www.AnalystsReview.com/03252014/SNTA/report.pdf
--
ZIOPHARM Oncology, Inc. Analyst Notes
On March 3, 2014, ZIOPHARM
Oncology, Inc. (Ziopharm) reported its Q4 2013 and full-year 2013
financial results. The Company reported Q4 2013 net loss of
$8.9 million or $0.09 per basic and diluted share, compared to
$30.2 million or $0.37 per basic and diluted share in Q4 2012.
Full year 2013, net loss was $57.1
million or $0.66 per share,
compared to $96.1 million or
$1.22 per share in full-year 2012.
Ziopharm informed that it expects to file several investigational
new drug (IND) applications for novel, multigenic gene therapies
through 2015. The full analyst notes on ZIOPHARM Oncology, Inc. are
available to download free of charge at:
http://www.AnalystsReview.com/03252014/ZIOP/report.pdf
--
Aastrom Biosciences, Inc. Analyst Notes
On March 13, 2014, Aastrom
Biosciences, Inc. (Aastrom) reported its Q4 2013 and full-year 2013
financial results. For the quarter, the Company reported net loss
of $2.9 million or $0.65 per share, compared to 6.7 million or
$3.60 per share in Q4 2012. For full
year 2013, net loss was $15.6 million
or $6.95 per share, compared to
$29.5 million or $16.25 per share in full-year 2012. According to
Aastrom, the substantial decrease in net loss during both the
periods on YoY basis is primarily due to decreases in research and
development and general and administrative expenses and the
non-cash change in the fair value of warrants. "With the completion
of a number of operational and financial initiatives in 2013, we
are well-positioned to continue to build on our momentum in
advancing our ongoing ixmyelocel-T clinical programs, exploring new
indications for ixmyelocel-T and pursuing promising new business
opportunities in 2014," said President and CEO Nick Colangelo. The full analyst notes on
Aastrom Biosciences, Inc. are available to download free of charge
at:
http://www.AnalystsReview.com/03252014/ASTM/report.pdf
--
Agios Pharmaceuticals, Inc. Analyst Notes
On March 19 2014, Agios
Pharmaceuticals, Inc. (Agios) announced the enrollment of the first
patient in its Phase 1 Study of AG-120 in patients with Advanced
Hematologic Malignancies with an isocitrate dehydrogenase-1 or IDH1
Mutation. According to the Company, AG-120 is an orally available,
selective, potent inhibitor of the mutated IDH1 protein, making it
the first targeted therapeutic candidate to treat patients with
cancers that harbor the IDH1 mutation. David Schenkein, M.D., CEO of Agios commented,
"Initiation of this study also represents a significant milestone
for Agios, as we have exclusive U.S. rights for the IDH1 program,
as well as for our partner Celgene, who has an option on IDH1
program rights in the rest of the world. Most importantly, we
believe this program has the potential to change the treatment of
cancer and help patients." The Company informed that AG-120 is a
part of Agios' global strategic collaboration with Celgene
Corporation. The full analyst notes on Agios Pharmaceuticals, Inc.
are available to download free of charge at:
http://www.AnalystsReview.com/03252014/AGIO/report.pdf
--
OncoMed Pharmaceuticals, Inc. Analyst Notes
On March 18, 2014, OncoMed
Pharmaceuticals, Inc. (OncoMed) reported its Q4 2013 and full-year
2013 financial results. For the quarter, revenues totaled
$19.0 million, compared to
$6.9 million in Q4 2012. Net loss
during the quarter remained unchanged from Q4 2012 at $4.3 million. Net loss per diluted share was
$0.15 in Q4 2013, compared to
$4.01 per diluted share in Q4 2012.
For full year 2013, revenues increased to $37.8 million from $24.7
million in full year 2012, primarily attributable to
collaborative revenues in the form of milestone payments from Bayer
associated with the vantictumab and OMP-54F28 program received in
Q4 2013 and the amortization of upfront payments from OncoMed's
agreements with GSK, Bayer and Celgene. Net loss was $26.1 million or $1.93 per diluted share in full year 2013,
compared to $22.2 million or
$21.30 per diluted share in full year
2012. The full analyst notes on OncoMed Pharmaceuticals, Inc. are
available to download free of charge at:
http://www.AnalystsReview.com/03252014/OMED/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
-
For any urgent concerns or inquiries,
please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Analysts Review